Literature DB >> 17172780

5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users.

Jim McCambridge1, Adam Winstock, Neil Hunt, Luke Mitcheson.   

Abstract

AIMS: To describe and assess trends in the use of hallucinogens and other adjunct drugs over a 5-year period.
DESIGN: Repeated-measures cross-sectional survey. SETTING AND PARTICIPANTS: Annual magazine-based survey targeting people who use drugs in dance contexts. MEASUREMENTS: Lifetime use prevalence (ever used); age of first use; current use prevalence (any use within the last month), and extent of use within the last month (number of days used) for LSD, psilocybin, ketamine, GHB and nitrates.
FINDINGS: Prevalence increases for psilocybin, ketamine, GHB and nitrates use have been detected, with a sharp recent rise in current psilocybin use in 2002-2003 contrasting with more gradual and comprehensive evidence of increased ketamine use throughout the period 1999-2003. The declining prevalence of LSD use in general population surveys is replicated in this sentinel population study.
CONCLUSIONS: The rise in prevalence of hallucinogen and other adjunct drugs identified among dance drug users may be mirrored by wider prevalence increases among young people with a consequent need to study these trends carefully and to develop effective interventions, where required.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17172780     DOI: 10.1159/000095816

Source DB:  PubMed          Journal:  Eur Addict Res        ISSN: 1022-6877            Impact factor:   3.015


  15 in total

Review 1.  Glutamatergic model psychoses: prediction error, learning, and inference.

Authors:  Philip R Corlett; Garry D Honey; John H Krystal; Paul C Fletcher
Journal:  Neuropsychopharmacology       Date:  2010-09-22       Impact factor: 7.853

2.  Reply to: Rapid antidepressant effects and abuse liability of ketamine.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-05       Impact factor: 4.530

Review 3.  A brief history of the development of antidepressant drugs: from monoamines to glutamate.

Authors:  Todd M Hillhouse; Joseph H Porter
Journal:  Exp Clin Psychopharmacol       Date:  2015-02       Impact factor: 3.157

4.  Comparison of antidepressant-like and abuse-related effects of phencyclidine in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Drug Dev Res       Date:  2014-10-15       Impact factor: 4.360

5.  Abuse liability profile of three substituted tryptamines.

Authors:  Michael B Gatch; Michael J Forster; Aaron Janowsky; Amy J Eshleman
Journal:  J Pharmacol Exp Ther       Date:  2011-04-07       Impact factor: 4.030

6.  Dissociable effects of the noncompetitive NMDA receptor antagonists ketamine and MK-801 on intracranial self-stimulation in rats.

Authors:  Todd M Hillhouse; Joseph H Porter; S Stevens Negus
Journal:  Psychopharmacology (Berl)       Date:  2014-02-13       Impact factor: 4.530

7.  Sit Down to Float: The Cultural Meaning of Ketamine Use in Hong Kong.

Authors:  Karen Joe-Laidler; Geoffrey Hunt
Journal:  Addict Res Theory       Date:  2008-06-01

Review 8.  Repeated ketamine administration alters N-methyl-D-aspartic acid receptor subunit gene expression: implication of genetic vulnerability for ketamine abuse and ketamine psychosis in humans.

Authors:  Ke Xu; Robert H Lipsky
Journal:  Exp Biol Med (Maywood)       Date:  2014-09-21

9.  Investigation of the Structure-Activity Relationships of Psilocybin Analogues.

Authors:  Adam K Klein; Muhammad Chatha; Lauren J Laskowski; Emilie I Anderson; Simon D Brandt; Stephen J Chapman; John D McCorvy; Adam L Halberstadt
Journal:  ACS Pharmacol Transl Sci       Date:  2020-12-14

10.  Improvement in the pre-hospital care of recreational drug users through the development of club specific ambulance referral guidelines.

Authors:  David M Wood; Shaun L Greene; Graham Alldus; Denise Huggett; Michelle Nicolaou; Kerry Chapman; Fionna Moore; Kim Heather; Nicola Drake; Paul I Dargan
Journal:  Subst Abuse Treat Prev Policy       Date:  2008-06-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.